← board
MDNAF
Medicenna Therapeutics, Inc.distress 6/10 · elevated risk$0.24-1%today-80% from 52w high
Oncology 1
Lead: Solid Tumor · target PD-1
Revenue
pre-revenue
Liquidity
$6M
Runway
0.3 yrs
Shares 1y
+30%
Price & events
-65.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.2%
1D
-5.1%
1W
-20.3%
1M
-43.9%
3M
-65.3%
6M
-59.3%
1Y
-83.0%
2Y
-89.2%
5Y
-94.6%
All
Overview
- Market Cap
- $16.92M
- Volume
- 12.40K
- 52 Week Range
- $0.24 – $1.19
- Total Shares
- 69.64M
- Float Shares
- 74.39M
- Short %
- 0.70%
- % Held by Insiders
- 19.40%
- % Held by Institutions
- 0.00%
- RVOL
- 0.18x
- Beta
- 1.89
Pipeline stages · 1 programs
MDNA11, Pembrolizumab (KEYTRUDA®)PD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06-30 | Phase 1/2 | MDNA11, Pembrolizumab (KEYTRUDA®) | Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer | 115 | recruiting |
Catalyst news & presentations · 1
- 2026-07-30Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 69,637,469 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $3 (+1237% upside) · 2 analysts
- 2024-12-06HC Wainwright & Co.Buy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-22What's Going On With Medicenna Therapeutics Corp Stock Wednesday? - Wealth Awesome
- 2026-07-17Why Medicenna Therapeutics Corp stock is rising today - Wealth Awesome
- 2026-07-16What's Going On With Medicenna Therapeutics Corp Stock Wednesday? - Wealth Awesome
- 2026-07-14Why Medicenna Therapeutics Corp stock is sliding today - Wealth Awesome
- 2026-07-06MDNAF SEC Filings - Medicenna Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
- 2026-07-02Medicenna stock price target maintained at $2.50 by H.C. Wainwright - Investing.com Canada
- 2026-06-29Why Medicenna Therapeutics Corp stock is sliding today - Wealth Awesome
- 2026-06-26Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.